Bonus BioGroup

Viable Tissue-regenerating Bone Grafts

Health Tech & Life Sciences
Public on TASE on Feb, 2012<br>

Company Overview

Snapshot

Founded in October 1981 by Shai Meretzki and Prof. Avinoam Kadouri (late), Bonus BioGroup operates with 11–50 employees. The company has raised a total of $25.6M across 5 funding rounds from 2 investors. Bonus BioGroup became public on TASE in February 2012.

Business overview

Bonus BioGroup is a biotechnology company focused on developing tissue-regenerating, viable bone grafts. The company specializes in cell therapy and tissue-engineering products, utilizing autologous bone implants to facilitate efficient bone transplantation and provide cell-based bone replacement for repairing bone lesions. Its core product, BonoFill, is a method for growing high-density 3D bone grafts from a patient's own cells, constructed in multiple layers within a bioreactor system. This technology enables the ex vivo construction of customized bone grafts, promoting acceptance and preventing immune reactions or rejection, serving the health tech and life sciences sectors.

Strategic signal

In February 2025, Bonus BioGroup announced that the U.S. Food and Drug Administration (FDA) granted clearance for an Investigational New Drug (IND) Application for its MesenCure™ Phase III Clinical Study in Respiratory Distress. This FDA clearance signals a significant advancement in the company's clinical development pipeline, validating the potential of MesenCure™ and opening the path for late-stage clinical trials in a critical therapeutic area, which could substantially impact future revenue streams and market positioning.

Company Intelligence Q&A

When did Bonus BioGroup become a public company?
Bonus BioGroup became public on TASE in February 2012.
What was a key regulatory milestone for Bonus BioGroup in February 2025?
In February 2025, Bonus BioGroup announced U.S. Food and Drug Administration (FDA) clearance of an Investigational New Drug (IND) Application for its MesenCure™ Phase III Clinical Study in Respiratory Distress.
What patent approval did Bonus BioGroup receive in September 2024?
In September 2024, Bonus BioGroup received patent approval from the European and English patent offices.
What was a notable leadership appointment for Bonus BioGroup in July 2025?
In July 2025, Bonus BioGroup appointed Professor Edwin M. Horwitz, MD, PhD, a renowned cell therapy leader, to its Advisory Board.
What was the outcome of Bonus BioGroup's Phase II trial for MesenCure in January 2022?
In January 2022, Bonus BioGroup submitted outstanding Phase II trial results for MesenCure, a treatment for severe COVID-19, to the Israeli Ministry of Health.

External links